EcoR1 Capital

About The Fund

EcoR1 Capital LLC is an investment advisory firm that specializes in the biotechnology and healthcare sectors. Founded in 2012 and based in San Francisco, California, EcoR1 focuses on investing in companies that are at the forefront of scientific innovation, particularly within the context of untreated diseases. Their investment approach embodies a commitment to nurture lasting relationships, expand potential through science, and drive progress in medical research. The firm operates with a keen interest in companies that are developing bleeding-edge science, pursuing high-quality scientific endeavors with strong business fundamentals. EcoR1's investment range spans from $10 million to $110 million, signaling versatility in supporting both emerging and more established biotechnology ventures. The firm is steered by Oleg Nodelman, the Founder and Portfolio Manager, who brings nearly twenty years of experience in biotech investing and a deep relationship network within the biotech and scientific communities. The leadership team is composed of experts with diverse backgrounds in finance, science, and compliance, illustrating a comprehensive approach to investments. EcoR1's portfolio includes a wide array of companies, from those pioneering epitranscriptome regulation to entities focusing on gene therapies, targeted radiopharmaceuticals, novel cancer therapeutics, and more. By taking an active role in investment decisions and partnering with industry leaders, EcoR1 aims to foster transformative cell therapies and next-generation treatments that can impact the lives of patients worldwide. They believe that people are a critical factor in any investment opportunity and place a strong emphasis on supporting drug hunters and companies with gutsy management teams. Always on the lookout for exceptional opportunities, EcoR1 is committed to advancing the most promising and innovative biotech solutions.